TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

DIAGNOSING HAE

Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent attacks of subcutaneous or submucosal edema that can affect the face, respiratory tract, extremities, gastrointestinal tract, genitalia or other parts of the body.1

Although a general lack of awareness and misunderstanding of symptoms can contribute to delays in diagnosis, once HAE is suspected, diagnostic methods have been established.2,3

Camila, a real TAKHZYRO® (lanadelumab-flyo) patient, sitting with her husband Jorge.
Camila
Jorge
Camila
Jorge

References: 1. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329–336. 2. Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80(7):391-398. 3. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update 2018;73(8):1575-1596. Allergy. doi:10.1111/all.13384 4. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–1036. 5. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 6. Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016 May 2;12:701-11. doi:10.2147/TCRM.S86293 7. Banerji A, Li Y, Busse P, et al. Hereditary angioedema from the patient's perspective: A follow-up patient survey. Allergy Asthma Proc. 2018 May 1;39(3):212-223. doi:10.2500/aap.2018.39.4123 8. Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020 Jun;124(6):600-607. doi:10.1016/j.anai.2020.02.018 9. Bork K, Bernstein JA, Machnig T, Craig TJ. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. J Emerg Med. 2016 Apr;50(4):567-80.e1. doi:10.1016/j.jemermed.2015.11.008